CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $31.98M, lower than 95% of all stocks globally
- PositionOperating margin is -25404.5%, lower than 95% of its Biotechnology peers (median -38%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
357.63MUSDvs all stocks (USD)
Revenue (TTM)
31.98MUSDvs all stocks (USD)
Profit Margin
-184.60%vs Biotechnology peers
Beta
0.5330xvs all stocks
52-Week Change
141.87%vs all stocks
Market Capitalization
357.63MUSDvs all stocks (USD)
Enterprise Value
328.52MUSDvs all stocks (USD)
Forward P/E
-3.94xvs Biotechnology peers
Price to Sales (TTM)
11.18xvs Biotechnology peers
Price to Book (MRQ)
18.54xvs Biotechnology peers
Enterprise to Revenue
10.27xvs Biotechnology peers
Enterprise to EBITDA
-5.70xvs Biotechnology peers
Gross Margin
71.59%vs Biotechnology peers
Profit Margin
-184.60%vs Biotechnology peers
Return on Assets (TTM)
-45.73%vs Biotechnology peers
Return on Equity (TTM)
-397.30%vs Biotechnology peers
Revenue (TTM)
31.98MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.5370USDUpdated Sep 28, 2026Quarterly Revenue Growth
-89.50%vs Biotechnology peers
Gross Profit (TTM)
31.82MUSDvs all stocks (USD)
EBITDA (TTM)
-57.64MUSDvs all stocks (USD)
Net Income (TTM)
-59.57MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-89.47%vs Biotechnology peers
Operating Cash Flow (TTM)
-58.32MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-31.81MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
33.48MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
190.00KUSDFY2025 · Dec 31, 2025Gross Profit
33.29MUSDFY2025 · Dec 31, 2025Operating Income
-51.81MUSDvs all stocks (USD)
Pre-tax Income
-52.70MUSDFY2025 · Dec 31, 2025Net Income
-52.70MUSDFY2025 · Dec 31, 2025EBIT
-51.55MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-51.48MUSDFY2025 · Dec 31, 2025Research & Development
58.19MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
26.91MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.15MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-52.70MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-54.45MUSDFY2025 · Dec 31, 2025Free Cash Flow
-54.94MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
34.69MUSDFY2025 · Dec 31, 2025Interest Paid
1.45MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-52.70MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
327.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
11.98MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.06MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-16.11MUSDFY2025 · Dec 31, 2025Capital Expenditures
-489.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-76.31MUSDFY2025 · Dec 31, 2025Sale of Investments
49.86MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-26.94MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
16.36MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
88.24MUSDFY2025 · Dec 31, 2025Shares Outstanding
60.11MSharesUpdated Sep 28, 2026Float Shares
32.95MSharesUpdated Sep 28, 2026Shares Short
2.37MSharesUpdated Sep 28, 2026Short Ratio
5.97daysvs all stocks
Short % of Shares Outstanding
6.41%vs all stocks
% Held by Insiders
24.45%vs all stocks
% Held by Institutions
47.66%vs all stocks
Total Cash (MRQ)
109.96MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.83USDUpdated Sep 28, 2026Total Debt (MRQ)
70.76MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
2.41xvs Biotechnology peers
Current Ratio (MRQ)
8.26xvs Biotechnology peers
Book Value per Share (MRQ)
0.3210USDUpdated Sep 28, 2026Total Assets
114.86MUSDvs all stocks (USD)
Total Current Assets
107.91MUSDFY2025 · Dec 31, 2025Total Liabilities
61.29MUSDFY2025 · Dec 31, 2025Total Non-current Assets
6.95MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
44.55MUSDFY2025 · Dec 31, 2025Total Current Liabilities
16.74MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
34.69MUSDFY2025 · Dec 31, 2025Other Short-term Investments
71.82MUSDFY2025 · Dec 31, 2025Accounts Receivable
95.00KUSDFY2025 · Dec 31, 2025Inventory
310.00KUSDFY2025 · Dec 31, 2025Accounts Payable
6.09MUSDFY2025 · Dec 31, 2025Short-term Debt
751.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Long-term Debt
15.20MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
16.79MUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-362.58MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
53.57MUSDvs all stocks (USD)
52-Week Low
2.40USDUpdated Sep 28, 202652-Week High
6.48USDUpdated Sep 28, 202652-Week Change
141.87%vs all stocks
Beta
0.5330xvs all stocks
50-Day MA
4.86USDUpdated Sep 28, 2026200-Day MA
4.35USDUpdated Sep 28, 2026Avg 10-Day Volume
398.78KSharesUpdated Sep 28, 2026Avg 30-Day Volume
395.68KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.8400USDUpdated Sep 28, 2026Other Income / Expense
254.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -25404.5%, lower than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: -254.045Industry median: -0.38Industry P5: -43.63Peers compared: 260
Return on equity is -397.3%, lower than 95% of its Biotechnology peers (median -22.3%)Significant
Return on equity: -3.97Industry median: -0.22Industry P5: -1.57Peers compared: 260
Debt-to-equity is 2.41×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 2.41Industry median: 0.07Industry P95: 0.93Peers compared: 260
Price-to-book is 18.54×, higher than 95% of its Biotechnology peers (median 2.86×)Significant
Price-to-book: 18.54Industry median: 2.86Industry P95: 13.08Peers compared: 260
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.72Profit Margin: -1.85
Significant cash reserves alongside high leverageNotable
Cash (USD): 109,963,000Total Debt (USD): 70,760,000Debt-to-Equity: 2.41
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 8.26Altman Z-Score: -1.16
Financial Health
Altman Z-Score -1.16: distress zoneCritical
Altman Z-Score: -1.16
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $31.98M, lower than 95% of all stocks globallySignificant
Revenue (USD): 31,976,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
CapsoVision, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Qinghai Spring Medicinal Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Solara Active Pharma Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cabaletta Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shoulder Innovations, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shin Poong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu GDK Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
C4 Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule